pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$CLYMClimb Bio, Inc.

$CLYM
Wellesley Hills, MA, USupdated 2mo ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
budoprutug
Membranous Glomerulonephritis

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)recruitingn=30
  • phase2A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathyrecruitingn=45
  • phase1A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)recruitingn=30
  • phase2A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)recruitingn=24
  • EP1A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteersactive not recruitingn=38
  • phase1A Phase 1 Study of CLYM116 in Normal Healthy Volunteersrecruitingn=48

Insider activity

source: SEC Form 4

open-market buys + sells

  • Feb 26, 26SELLThomas Stephen Basil· director16,313 sh @ $7.01−$114K↗
  • Feb 25, 26SELLThomas Stephen Basil· director33,687 sh @ $7.00−$236K↗
🐶 Hiring Signal
No open roles indexed yet — view Climb Bio, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$CLYM
SEC CIK
0001768446
country
US
source
sec_tickers
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 8m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?